Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07753369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Bendamustine injection、 Rituximab injection 、Lenalidomide Capsules (Drug), TQB3909 Tablets (Drug) to Bendamustine Injection (Drug), Lenalidomide Capsules (Drug), Rituximab injection (Drug), TQB3909 Tablets (Drug)v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To Evaluate the Efficacy and Safety of TQB3909 Tablets versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial Details
NCT Number NCT07753369
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia
Enrollment 128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov